Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
Primary Sjögren's syndrome (pSS) is a common chronic auto-immune disease, characterised by
inflammation of the exocrine glands, resulting in progressive dryness of the eyes and the
mouth. Furthermore, many patients experience extraglandular symptoms such as restricting
fatigue. Currently, biological agents have been introduced in various systemic autoimmune
diseases such as rheumatoid arthritis and systemic lupus erythematosus. No biological agent
has yet been approved for the treatment of pSS. In an open-label study, we have shown that
abatacept treatment of pSS patients has promising results (Meiners et al., 2014). Therefore,
the aim of this study is to evaluate efficacy and safety of subcutaneous abatacept treatment
in pSS in a larger and randomized clinical trial.